NYC-based clinical-stage biopharmaceutical company Mind Medicine (MindMed) announced that Swiss collaborators at the University Hospital Basel (UHB) and the University Hospital of Psychiatry have released positive topline data from a double-blind, investigator-initiated trial evaluating lysergide in the treatment of major depressive disorder (MDD).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,